CURIS LIFESCIENCES (CURIS-SM) Share Price Falls 9.63% Today
- September 10, 2026
- Posted by: Harsh Piplani
- Category: News
CURIS LIFESCIENCES Share Price fell to Rs 197.6 on 10 September 2026, a decline of 9.63% from the previous close of Rs 218.65. The stock lost Rs 21.05 on the day, while the company’s market capitalisation stood at Rs 176.77 crore. In today’s session, the Micro Cap pharmaceutical stock opened at Rs 228.8, which was also the day’s high, and later moved down to Rs 197.6, the day’s low.
For readers tracking CURIS LIFESCIENCES Share Price Today, the data confirms a sharp one-day fall, but it does not establish a company-specific reason for the move. That means the most useful approach is to separate verified market action from speculation. The available numbers allow a direct look at price behaviour, valuation, profitability, sector benchmarks and peer comparison within the Healthcare and Pharmaceuticals & Drugs space.
That broader context matters because the company combines a small market-cap profile with notable reported return ratios. So while price weakness is the immediate event, the stock also stands out for how its P/E, P/B, ROE and ROCE compare with the wider industry dataset. This article focuses on those measurable facts only.
CURIS LIFESCIENCES (CURIS-SM) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 197.6 |
| Previous Close | Rs 218.65 |
| Today's Move | -Rs 21.05 (-9.63%) |
| Open | Rs 228.8 |
| High | Rs 228.8 |
| Low | Rs 197.6 |
| Turnover | Rs 0.63 crore |
| Market Capitalisation | Rs 176.77 crore |
| Market Cap Category | Micro Cap |
Intraday structure is one of the clearest parts of the update. The stock opened at Rs 228.8 and never traded above that level. It later declined to Rs 197.6, which matched the day’s low at the time of the article. When a stock opens at the day’s high and trades down to the day’s low, it points to sustained pressure during the session rather than a brief fluctuation.
Turnover of Rs 0.63 crore shows there was visible trading activity behind the move. In a much larger company, the same turnover might not mean much, but against a market capitalisation of Rs 176.77 crore it still gives a sense of active participation. Because CURIS LIFESCIENCES Share Price belongs to a Micro Cap stock, single-session moves of this scale often receive closer tracking from short-term and fundamentally focused market participants alike.
The factual takeaway from the session is straightforward: the stock fell throughout the day, ended near the low and closed the gap sharply from the previous close. From here, analysis naturally shifts from price behaviour to whether the stock’s existing financial ratios present a different picture from the day’s trading weakness.
CURIS LIFESCIENCES (CURIS-SM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 176.77 crore |
| P/E Ratio | 25.56x |
| P/B Ratio | 3.73x |
| ROE | 55.25% |
| ROCE | 34.25% |
| EPS | Rs 8.56 |
| Book Value Per Share | Rs 58.58 |
| Dividend Yield | 0% |
On fundamentals, the supplied numbers present a business that is small in size but not without notable ratios. The stock trades at a P/E of 25.56 and a P/B of 3.73. EPS stands at Rs 8.56, while book value per share is Rs 58.58. Dividend yield is 0 based on the available dataset.
The standout figures are profitability ratios. ROE is listed at 55.25% and ROCE at 34.25%. Those numbers are strong in absolute terms and become even more relevant when set beside industry medians and major listed peers. This does not explain the day’s decline, but it does show why the stock remains worth watching after a weak trading session.
From a valuation point of view, CURIS LIFESCIENCES Share Price does not appear to sit at an extreme earnings multiple relative to the sector data supplied here. At the same time, the company’s Micro Cap classification means market moves can remain sharp even when headline ratios look comparatively reasonable. In other words, valuation and profitability offer context, not an explanation.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 25.56x |
| Benchmark Median P/E | 32.79x |
| Benchmark Average P/E | 49.1x |
| Benchmark P/E Range | 3.4x to 706.55x |
| Company P/B Ratio | 3.73x |
| Benchmark Median P/B | 3x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 55.25% |
| Benchmark Median ROE | 11.83% |
| Benchmark Average ROE | 11.27% |
| Company ROCE | 34.25% |
| Benchmark Median ROCE | 13.75% |
| Benchmark Average ROCE | 13.75% |
| Company Market Capitalisation | Rs 176.77 crore |
| Benchmark Median Market Cap | Rs 759.52 crore |
| Benchmark Average Market Cap | Rs 14,312.16 crore |
CURIS LIFESCIENCES operates in the Healthcare sector under Pharmaceuticals & Drugs, and the benchmark set covers 200 companies in the same industry. Within that universe, the company’s P/E of 25.56 is below the median of 32.79 and below the average of 49.1. That places it below the middle of the industry on earnings valuation, at least on the supplied figures.
Its P/B ratio of 3.73 is above the industry median of 3, but below the average of 4.44. The biggest difference shows up in returns: ROE of 55.25% is far above the benchmark median of 11.83% and average of 11.27, while ROCE of 34.25% is well ahead of both the benchmark median and average of 13.75.
Size tells a different story. The company’s market capitalisation of Rs 176.77 crore is below the industry median of Rs 759.52 crore and far below the average of Rs 14,312.16 crore. So the sector view suggests a small company with stronger reported return ratios than the broader peer set, but with the risk profile that often comes with a Micro Cap stock.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,51,338.9 | 37.06 | 5.18 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,54,068.03 | 86.06 | 14.25 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,88,767.06 | 86.01 | 20.9 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,14,712.94 | 24.95 | 4.18 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,11,803.57 | 32.79 | 3.14 | 11.83 | 16 |
Compared with major listed pharma peers, CURIS LIFESCIENCES is dramatically smaller by market value. Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla all have market capitalisations many times larger than Rs 176.77 crore. That scale difference matters because larger companies often show different liquidity, business diversification and trading behaviour than Micro Cap names.
On earnings valuation, the company’s P/E of 25.56 is lower than Sun Pharma at 37.06, Divi’s at 86.06, Torrent at 86.01 and Cipla at 32.79, while it is close to Zydus Lifesciences at 24.95. On price-to-book, 3.73 is below Sun Pharma, Divi’s and Torrent, but above Cipla and slightly below Zydus only by comparison of listed figures here.
The strongest relative numbers are profitability ratios. CURIS LIFESCIENCES reports ROE of 55.25% and ROCE of 34.25%, both above the figures shown for the peer group in this dataset. That does not lessen the significance of today’s decline, but it explains why investors may continue to watch the stock despite the weak session.
Why Investors Are Watching CURIS LIFESCIENCES
- The stock fell 9.63% in one session, from Rs 218.65 to Rs 197.6.
- It opened at Rs 228.8, which was also the day’s high, and later touched the day’s low.
- The company trades at 25.56x P/E and 3.73x P/B on the supplied data.
- ROE of 55.25% and ROCE of 34.25% are well above industry medians.
- Its Rs 176.77 crore market capitalisation places it in the Micro Cap category.
About CURIS LIFESCIENCES
CURIS LIFESCIENCES is classified under the Healthcare sector and the Pharmaceuticals & Drugs industry. Within the broader listed healthcare space, it sits alongside much larger peers, but the company itself remains a Micro Cap based on market capitalisation of Rs 176.77 crore. That makes the stock relevant to investors who track smaller healthcare counters and compare them with sector-level valuation and profitability data.
Track CURIS LIFESCIENCES Share Price on Univest
UseUnivest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Readers can track CURIS LIFESCIENCES (CURIS-SM) share price on Univest for the latest market data. For investors following CURIS LIFESCIENCES Share Price closely, live price, valuation ratios, market capitalisation and sector context can help place a one-day decline within a broader analytical framework.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did CURIS LIFESCIENCES Share Price fall today?
Ans. The supplied data confirms that CURIS LIFESCIENCES Share Price fell 9.63% today from Rs 218.65 to Rs 197.6. However, the dataset does not establish any company-specific catalyst for the decline.
What is CURIS LIFESCIENCES Share Price today?
Ans. At the time of the article update, the stock was trading at Rs 197.6, down Rs 21.05 from the previous close. The previous close was Rs 218.65. The stock moved 9.63% lower during the session.
What is the market capitalisation of CURIS LIFESCIENCES?
Ans. The company’s market capitalisation is Rs 176.77 crore, placing it in the Micro Cap category. The company operates in the Healthcare sector. Its P/E ratio is 25.56x. ROE is 55.25% and ROCE is 34.25%.
How does CURIS LIFESCIENCES compare with major pharma peers?
Ans. The company is far smaller than peers such as Sun Pharma, Divi’s, Torrent, Zydus and Cipla by market capitalisation. However, its P/E is lower than several of those peers, and its reported ROE and ROCE are higher than the peer.
